REN001
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
McArdle Disease
Conditions
McArdle Disease
Trial Timeline
Dec 10, 2019 → Oct 11, 2021
NCT ID
NCT04226274About REN001
REN001 is a phase 1 stage product being developed by OnKure Therapeutics for McArdle Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04226274. Target conditions include McArdle Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05267574 | Phase 2/3 | Terminated |
| NCT04226274 | Phase 1 | Completed |
| NCT03862846 | Phase 1 | Terminated |